Equity Overview
Price & Market Data
Price: $10.09
Daily Change: +$0.07 / 0.69%
Range: $9.79 - $10.11
Market Cap: $535,678,112
Volume: 119,286
Performance Metrics
1 Week: 17.19%
1 Month: -2.13%
3 Months: -37.87%
6 Months: -64.43%
1 Year: -34.90%
YTD: -27.41%
Company Details
Employees: 60
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.